Dimercaptosuccinic Acid: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: March 6, 2026🚩 Report this page

Dimercaptosuccinic Acid

Active ingredient

Sold as RENOCIS

GB MHRA

Drug class: -
Availability: See label
Markets covered: 1
Products on record: 1

Overview

Dimercaptosuccinic Acid is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	1	March 6, 2026

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised March 6, 2026[1]

This medicinal product is for diagnostic use only. After radiolabelling with sodium pertechnetate (99mTc) solution, the solution of technetium (99mTc) succimer obtained is indicated for: - the study of the renal cortex morphology. - the study of individual kidney function.
- the location of ectopic kidney.

How to take

Sources & citations

[1]MHRA (UK) · PL118760008 · revised March 6, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised March 6, 2026[1]

The adverse events are presented in the table below by the MedDRA System Organ Class and with a not known frequency (cannot be estimated from the available data): MedDRA Body system SOCs Preferred term Frequency Immune system disorders Hypersensitivity Not known Allergic reactions have been reported in the literature.
Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects. 06 mSv when the maximal recommended activity of 120 MBq is administered these adverse reactions are expected to occur with a low probability.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised March 6, 2026[1]

4. Image acquisition The images can be obtained by static (planar or tomographic) acquisitions between 1 to 3 hours post-injection. Where there is renal impairment or obstruction, delayed views may be needed (6 to 24 hours respectively).
1 or to any of the components of the labelled radiopharmaceutical. 4 Special warnings and precautions for use Potential for hypersensitivity or anaphylactic reactions If hypersensitivity or anaphylactic reactions occur, the administration of the medicinal product must be discontinued immediately and intravenous treatment initiated, if necessary.
To enable immediate action in emergencies, the necessary medicinal products and equipment such as endotracheal tube and ventilator must be immediately available. Individual benefit/risk justification For each patient, the radiation exposure must be justifiable by the likely benefit.
The activity administered should in every case be as low as reasonably achievable to obtain the required diagnostic information. 2). 2. Careful consideration of the indication is required since the effective dose per MBq is higher than in adults (see section 11).
Patient preparation The patient should be well hydrated before the start of the examination and urged to void as often as possible during the first hours after the examination in order to reduce radiation. After the procedure Close contact with infants and pregnant women should be restricted during 4 hours.
e. is essentially ‘sodium- free’. 6.

This is not medical advice. Consult a qualified healthcare professional.